Pharmacutical Atherosclerosis Treatment Drugs Market | Page 2

REPORT DESCRIPTION
Atherosclerosis Treatment Drugs Market – Overview
Increasing number of pipeline studies and rising involvement of key players for developing the treatment options for
atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. For Instance, in November 13,
2018, Bayer in collaboration with Janssen, LP started the clinical study for Rivaroxaban and Acetylsalicylic Acid to
build up the insights in treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with
acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in August
2021.
Moreover, technological advancement in the atherosclerosis treatment procedures is expected to boost the
atherosclerosis treatments drug market growth. For instance, in May 2017, Researchers at Ben-Gurion University
(BGU) and the Sheba Medical Center developed Nano polymer therapy, a new therapy for the treatment of
atherosclerosis. It prevents heart failure with a new biomedical polymer (E-selectin-targeting polymer) that reduces
arterial plaque and inflammation in the cardiovascular system. E-selectin-targeting polymer helps to reduce existing
plaque and impedes the further plaque formation. It also prevents arterial thrombosis, ischemia, myocardial
infarction, and strokes.
© Coherent market Insights. All Rights Reserved